Новый пробиотический штамм Streptococcus salivarius K12 в клинической практике | КМАХ

Новый пробиотический штамм Streptococcus salivarius K12 в клинической практике

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(2):92-99

​ Андреева И.В., Стецюк О.У.
10.36488/cmac.2019.2.92-99
пробиотики микробиота ротовой полости Streptococcus salivarius K12 инфекции верхних дыхательных путей тонзиллит фарингит острый средний отит галитоз
Раздел
Антимикробные препараты
Тип
Обзор
Публикация
Клиническая микробиология и антимикробная химиотерапия. 2019; 21(2):92-99

Аннотация

В последние десятилетия в клинической практике появились пробиотические штаммы для местного применения, в т.ч. в полости рта. Streptococcus salivarius K12 является перспективным пробиотиком для профилактики и лечения инфекций верхних дыхательных путей и ЛОР-органов и сохранения здоровья микробиоты ротовой полости. В обзоре представлены механизмы действия оральных пробиотиков и результаты клинических исследований по применению штамма S. salivarius K12 при различных нозологических формах.

Андреева Ирина Вениаминовна

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

Стецюк Ольга Ульяновна

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

  • 1. Food and Agricultural Organization/WHO. Guidelines for the evaluation of probiotics in food, 2002. In: Report of a Joint FAO/ WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Food and Agricultural Organization, Rome, Italy. Available at: www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
  • 2. Zarco M.F., Vess T.J., Ginsburg G.S. The oral microbiome in health and disease and the potential impact on personalized dental medicine. Oral Dis. 2012;18:109-120. DOI: 10.1111/j.1601-0825.2011.01851.x.
  • 3. Gao L., Xu T., Huang G., et al. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell. 2018;9:488-500. DOI: 10.1007/s13238-018-0548-1
  • 4. Hansen J.N. Nisin as a model food preservative. Crit Rev Food Sci Nutr. 1994;34:69-93. DOI: 10.1080/10408399409527650
  • 5. Sanders C.C., Sanders W.E. Enocin: an antibiotic produced by Streptococcus salivarius that may contribute to protection against infections due to Group A Streptococci. J Infect Dis. 1982;146:683-690. DOI: 10.1093/infdis/146.5.683
  • 6. Roos K., Hakansson E.G., Holm S. Effect of recolonisation with «interfering» alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. BMJ. 2001;322:210-212. DOI: 10.1136/ bmj.322.7280.210
  • 7. Hillman J.D., Mo J., McDonell E., et al. Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J Appl Microbiol. 2007;102:1209-1219. DOI: 10.1111/j.1365-2672.2007.03316.x
  • 8. Balakrishnan M., Simmonds R.S., Tagg J.R. Diverse activity spectra of bacteriocin-like inhibitory substances having activity against mutans streptococci. Caries Res. 2001;35:75-80. DOI: 10.1159/000047435
  • 9. Tong H., Chen W., Merritt J., et al. Streptococcus oligofermentans inhibits Streptococcus mutans through conversion of lactic acid into inhibitory H2O2: a possible counteroffensive strategy for interspecies competition. Mol Microbiol. 2007;63:872-880. DOI: 10.1111/j.1365-2958.2006.05546.x
  • 10. Kumar P.S., Leys E.J., Bryk J.M., et al. Changes in periodontal health status are associated with bacterial community shifts as assessed by quantitative 16S cloning and sequencing. J Clin Microbiol. 2006;44:3665-3673. DOI: 10.1128/JCM.00317-06
  • 11. Wescombe P.A., Heng N.C., Burton J.P., et al. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol. 2009;4:819-835. DOI: 10.2217/fmb.09.61
  • 12. Tagg J.R, Hale J.D., Wescombe P.A. BLIS-producing probiotics targeting the oral cavity. Microbiol Aust. 2012;33:103-105.
  • 13. Favier C.F., Vaughan E.E., De Vos W.M., et al. Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol. 2002;68:219-226. DOI: 10.1128/aem.68.1.219-226.2002
  • 14. Park H.K., Shim S.S., Kim S.Y., et al. Molecular analysis of colonized bacteria in a human newborn infant gut. J Microbiol. 2005;43:345-353.
  • 15. Wescombe P.A., Upton M., Dierksen K.P., et al. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol. 2006;72:1459-1466. DOI: 10.1128/AEM.72.2.1459-1466.2006
  • 16. Wescombe P.A., Burton J.P., Cadieux P.A., et al. Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie Van Leeuwenhoek. 2006;90:269-280. DOI: 10.1007/s10482-006-9081-y
  • 17. Wescombe P.A., Heng N.C., Burton J.P., et al. Something old and something new: an update on the amazing repertoire of bacteriocins produced by Streptococcus salivarius. Probiot Antimicrob Proteins. 2010;2:37-45. DOI: 10.1007/s12602-009-9026-7
  • 18. Burton J.P., Wescombe P.A., Moore C.J., et al. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006;72:3050-3053. DOI: 10.1128/ AEM.72.4.3050-3053.2006
  • 19. Burton J., Chilcott C., Wescombe P., et al. Extended safety data for the oral cavity probiotic Streptococcus salivarius K12. Probiot Antimicrob Protiens. 2010;2:135-144. DOI: 10.1007/s12602-010-9045-4
  • 20. Burton J.P., Cowley S., Simon R.R., et al. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2011;49:2356-2364. DOI: 10.1016/j.fct.2011.06.038
  • 21. Hyink O., Wescombe P.A., Upton M., et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol. 2007;73:1107-1113. DOI: 10.1128/AEM.02265-06
  • 22. Dierksen K.P., Tagg J.R. The influence of indigenous bacteriocinproducing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. In: Streptococci and Streptococcal Diseases Entering the New Millenium. Martin D.R., Tagg J.R. (Eds). Securacopy, Auckland, New Zealand, 2000; 81-85.
  • 23. Fantinato V.C., Jorge A.O., Shimizu M.T. Production of bacteriocin-like inhibitory substances (BLIS) by Streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Rev Microbiol. 1999;30:332-334. DOI: 10.1590/s0001-37141999000400007
  • 24. Santagati M., Scillato M., Patane F., et al. Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol Med Microbiol. 2012;65:23-31. DOI: 10.1111/j.1574-695X.2012.00928.x
  • 25. Guglielmetti S., Taverniti V., Minuzzo M., et al. Oral bacteria as potential probiotic for the pharyngeal mucosa. Appl Environ Microbiol. 2010;76:3948-3958. DOI: 10.1128/AEM.00109-10
  • 26. Horz H.P., Meinelt A., Houben B., et al. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007;22:126-130. DOI: 10.1111/j.1365-2672.2006.02837.x
  • 27. Burton J.P., Chilcott C.N., Moore C.J., et al. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol. 2006;100:754-764. DOI: 10.1111/j.1365-2672.2006.02837.x
  • 28. Power D.A., Burton J.P., Chilcott C.N., et al. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008;27:1261-1263. DOI: 10.1007/s10096-008-0569-4
  • 29. Di Pierro F., Colombo M., Giuliani M., et al. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 2016;20:4601-4606.
  • 30. Di Pierro F., Risso P., Poggi E., et al. Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in notrecurrent pediatric subjects. Minerva Pediatr. 2018;70:240-245. DOI: 10.23736/S0026-4946.18.05182-4
  • 31. Di Pierro F., Colombo M., Zanvit A., et al. Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Drug Healthc Patient Saf. 2016;8:77-81. DOI: 10.2147/DHPS. S117214
  • 32. Gregori G., Righi O., Risso P., et al. Reduction of group A betahemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. 2016;12:87-92. DOI: 10.2147/TCRM.S96134
  • 33. Di Pierro F., Di Pasquale D., Di Cicco M. Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. Int J Gen Med. 2015;8:303-308. DOI: 10.2147/IJGM.S92488
  • 34. Wilcox C.R., Stuart B., Leaver H., et al. Effectiveness of the probiotic Streptococcus salivarius K12 for the treatment and/or prevention of sore throat: a systematic review. Clin Microbiol Infect. 2019;25(6):673-680. DOI: 10.1016/j.cmi.2018.12.031
  • 35. Masdea L., Kulik E.M., Hauser-Gerspach I., et al. Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour. Arch Oral Biol. 2012;57:1041-1047. DOI: 10.1016/j.archoralbio.2012.02.011
  • 36. Kazor C.E., Mitchell P.M., Lee A.M., et al. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J Clin Microbiol. 2003;41:558-563. DOI: 10.1128/jcm.41.2.558-563.2003
  • 37. Jamali Z., Aminabadi N.A., Samiei M., et al. Impact of Chlorhexidine Pretreatment Followed by Probiotic Streptococcus salivarius Strain K12 on Halitosis in Children: A Randomised Controlled Clinical Trial. Oral Health Prev Dent. 2016;14(4):305-313. DOI: 10.3290/j.ohpd.a36521
  • 38. Holmes A.R., Gopal P.K., Jenkinson H.F. Adherence of Candida albicans to a cell surface polysaccharide receptor on Streptococcus gordonii. Infect Immun. 1995;63;1827-1834.
  • 39. Liljemark W.F., Gibbons R.J. Suppression of Candida albicans by human oral streptococci in gnotobiotic mice. Infect Immun. 1973;8:846-849.
  • 40. Nair R.G., Samaranayake L.P. The effect of oral commensal bacteria on candidal adhesion to human buccal epithelial cells in vitro. J Med Microbiol. 1996;45:179-185. DOI: 10.1099/00222615-45-3-179
  • 41. Nair R.G., Anil S., Samaranayake L.P. The effect of oral bacteria on Candida albicans germ-tube formation. APMIS. 2001;109:147-154. DOI: 10.1034/j.1600-0463.2001.d01-116.x
  • 42. Ishijima S.A., Hayama K., Burton J.P., et al. Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. Appl Environ Microbiol. 2012;78:2190-2199. DOI: 10.1128/AEM.07055-11
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились